ImmunoGen Inc IMGN announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine (pivekimab) in patients with frontline and relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer.
Enrollment continues in the frontline CADENZA cohort; top-line data is expected in 2024.
In frontline-treated patients, including those with de novo and PCHM, the objective response rate (ORR) is 80% (24/30 patients) with a composite complete remission (CCR) rate of 73% (22/30 patients), and an additional patient achieving a CR post-transplant.
The median duration of response (DOR) for all responders in frontline-treated patients was 12.7 months.
In R/R patients, the ORR was 33% (16/49 patients), with a CCR rate of 20% (10/49 patients), including those who previously failed intensive chemotherapy and/or transplant.
The median DOR for all responders in R/R patients was 7.1 months.
Pivekimab continues to exhibit manageable safety; no new safety signals were observed.
Price Action: IMGN shares are up 7.71% at $16.97 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
